Coherus Biosciences | CHRS - Interest Expense On Debt


Coherus Biosciences reported $2.25M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Akebia Therapeutics 349.66M 12.86M Jun/2026
ALKERMES USD 25.92M 5.03M Jun/2026
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
Amarin USD 3K 5K Dec/2024
Amgen USD 95.64B 94.98B Jun/2026
Baxter International USD 78M 20M Mar/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
Coherus Biosciences USD 2.25M 76K Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Fujifilm JPY 863M 429M Mar/2026
Gilead Sciences USD 247M 7M Jun/2026
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
Merck USD 525M 46M Jun/2026
Myriad Genetics USD 4.4M 600K Dec/2025
Pacira USD 3.62M 77K Jun/2026
Perrigo USD 7.61B 373.8M Jun/2026
Pfizer USD 667M 4M Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Teva Pharmaceutical Industries USD 195M 21M Jun/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xencor USD 7.35M 2.65M Jun/2026
Zoetis USD 61M 1000K Jun/2026